Opportunity Information: Apply for RFA AI 14 033
Apply for RFA AI 14 033
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Atopic Dermatitis Research Network (ADRN) (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Mar 20, 2014 and posted on Mar 19, 2014.
- Applicants must submit their applications by Jul 8, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $6,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Private institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts Native American tribal governments (Federally recognized) Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education For profit organizations other than small businesses State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Atopic Dermatitis Research Network (ADRN) (U19) funding opportunity (RFA-AI-14-033) is a National Institutes of Health (NIH) cooperative agreement designed to support a single, large, multi-project, multi-institution clinical research program focused on atopic dermatitis (AD). The core purpose is not just to fund individual studies, but to establish and run an organized network that can coordinate multiple clinical research efforts under one administrative and scientific umbrella. The awardee is expected to provide leadership for the network, manage the operational and administrative workload that comes with multi-site clinical research, and ensure the different projects function as an integrated program rather than isolated efforts.
Scientifically, the ADRN is centered on understanding skin host defense and why individuals with atopic dermatitis differ from healthy, non-atopic individuals in their responses to pathogens and immunologic challenges. The FOA highlights comparative research that looks at responses to infections and vaccines, with an emphasis on the underlying mechanisms that drive those responses. Key areas of interest include the skin barrier (how well the skin physically and chemically protects the body), and both adaptive and innate immunity (how the immune system responds immediately and over time). The announcement explicitly calls out viral and bacterial infections as focal points, reflecting the real-world clinical problem that many AD patients experience recurrent or more severe skin infections.
The opportunity also emphasizes modern mechanistic approaches, including genetic and epigenetic studies, to better characterize why susceptibility and immune response patterns differ across individuals. In addition, it expands the scope to include the microbiome, recognizing that microbial communities on the skin can shape inflammation, immune education, and resistance or vulnerability to infection. Beyond observational or mechanistic research, the FOA encourages work that leads toward clinical interventions aimed at enhancing host defense in AD, signaling interest in translation from biology to practical strategies that reduce infection risk or improve immune competence in the skin.
A notable feature of the FOA is its support for longitudinal studies, meaning research that follows participants over time rather than relying only on single time-point measurements. These longitudinal efforts are aimed at identifying and validating AD phenotypes, or subtypes of atopic dermatitis, based on clinical presentation and measurable biologic patterns. The phenotyping goals include correlating clinical features with immunologic responses in the skin and peripheral blood, as well as mapping patterns of cutaneous host defense. In practice, this type of work can help move the field toward more personalized approaches, where patient subgroups are defined not only by symptom severity but by immune and barrier biology that may predict infection risk or treatment response.
From an administrative and funding standpoint, this is a discretionary NIH award mechanism using a cooperative agreement (U19). Cooperative agreements typically involve substantial NIH programmatic involvement compared with standard grants, which fits the network model where coordination, shared standards, and consistent execution across sites are essential. The FOA anticipated one award, with an estimated total funding level of $6,000,000, underscoring that NIH intended to fund one central network structure rather than multiple competing networks under this announcement. There is no cost sharing or matching requirement.
Eligibility is broad across U.S.-based organizations, including public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit entities (with small businesses explicitly included), and a range of government entities (state, county, city/township, special district). It also includes tribal governments and tribally controlled institutions, as well as historically underserved institution types such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and others. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible; however, foreign components as defined by NIH policy are allowed, which can permit certain types of international collaboration within NIH rules while keeping the applicant organization domestic.
Key dates in the original posting show it was posted March 19, 2014, with an original and current closing date of July 8, 2014, and an archive date of August 8, 2014. The funding activity categories and CFDA numbers listed (93.855 and 93.856) place it within allergy/immunology and infectious diseases research domains, reflecting the intersection of dermatologic inflammation with infection susceptibility and immune defense.
In short, this FOA sought one institutional awardee to build and lead a coordinated clinical research network focused on the biology of host defense in atopic dermatitis. It prioritizes integrated, multi-site clinical studies comparing AD and non-atopic populations, with attention to barrier function, innate and adaptive immunity, infections and vaccine responses, genetics and epigenetics, microbiome influences, intervention development, and long-term phenotyping to define meaningful AD subgroups based on clinical and immunologic patterns.
FAQs: Atopic Dermatitis Research Network (ADRN) (U19) - RFA-AI-14-033
What is this funding opportunity?
This opportunity is the Atopic Dermatitis Research Network (ADRN) cooperative agreement (U19) under FOA RFA-AI-14-033. It is an NIH discretionary award intended to support a single, large, multi-project, multi-institution clinical research program focused on atopic dermatitis (AD).
What is the main purpose of the ADRN award?
The purpose is to establish and run an organized clinical research network, not just to fund separate individual studies. The network is expected to coordinate multiple clinical research efforts under one integrated administrative and scientific structure.
How many awards did NIH anticipate making?
The FOA anticipated one award, meaning NIH intended to fund one central network structure rather than multiple competing networks under this announcement.
What is the estimated total funding level?
The estimated total funding level listed for this FOA was $6,000,000.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
What grant mechanism is being used?
The mechanism is a cooperative agreement (U19). This is designed for situations where substantial NIH programmatic involvement is expected, which aligns with a network model that requires coordination and shared standards across sites.
What does it mean that this is a cooperative agreement?
In this context, it means the NIH expects a higher level of programmatic involvement than with standard research grants, consistent with the needs of a coordinated, multi-site clinical research network.
What kind of research is the ADRN focused on?
The ADRN is centered on understanding skin host defense in atopic dermatitis and why individuals with AD differ from healthy, non-atopic individuals in responses to pathogens and immunologic challenges.
Which scientific topics are specifically emphasized?
The FOA emphasizes comparative and mechanistic research, including: skin barrier function; innate and adaptive immune responses; responses to infections and vaccines; and the underlying mechanisms driving those responses in AD versus non-atopic individuals.
Are infections a key focus area?
Yes. Viral and bacterial infections are explicitly called out as focal points, reflecting the clinical problem of recurrent or more severe skin infections in many people with atopic dermatitis.
Does the FOA encourage vaccine-related research?
Yes. Comparative research examining responses to infections and vaccines is highlighted, with an emphasis on mechanisms behind differing responses.
Are genetic and epigenetic approaches included in the scope?
Yes. The FOA emphasizes modern mechanistic approaches, including genetic and epigenetic studies, to help characterize why susceptibility and immune response patterns differ across individuals.
Is the microbiome included in the research scope?
Yes. The scope expands to include the microbiome, recognizing that microbial communities on the skin can shape inflammation, immune education, and resistance or vulnerability to infection.
Does the FOA support work toward clinical interventions?
Yes. Beyond mechanistic and observational research, the FOA encourages work that leads toward clinical interventions aimed at enhancing host defense in atopic dermatitis.
Are longitudinal studies encouraged?
Yes. The FOA notably supports longitudinal studies that follow participants over time, rather than relying only on single time-point measurements.
What are the goals of the longitudinal studies described?
Longitudinal efforts are aimed at identifying and validating AD phenotypes (subtypes) based on clinical presentation and measurable biologic patterns, including correlations between clinical features and immunologic responses in skin and peripheral blood, and mapping patterns of cutaneous host defense.
What is meant by "phenotypes" in this FOA?
In this FOA, phenotypes refer to meaningful AD subtypes defined by clinical features together with biologic patterns (for example, immune and barrier biology) that may relate to infection risk or treatment response.
What kind of program structure is NIH expecting from the awardee?
NIH is expecting a single awardee to provide leadership for the network, manage the operational and administrative workload of multi-site clinical research, and ensure that the different projects function as an integrated program rather than isolated efforts.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizations, including public and private institutions of higher education; nonprofits (with and without 501(c)(3) status); for-profit entities (including small businesses); and government entities such as state, county, city/township, and special district governments. Tribal governments and tribally controlled institutions are also included, along with several categories of historically underserved institution types (for example, HBCUs, Hispanic-serving institutions, AANAPISIs, and Alaska Native and Native Hawaiian-serving institutions, among others).
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible to apply under this FOA.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible under this FOA.
Are foreign components allowed at all?
Yes. The FOA indicates that foreign components, as defined by NIH policy, are allowed. This can enable certain types of international collaboration within NIH rules while keeping the applicant organization domestic.
When was the opportunity posted and when did it close?
The FOA was posted on March 19, 2014. The original and current closing date was July 8, 2014. The archive date was August 8, 2014.
What research areas do the listed CFDA numbers relate to?
The CFDA numbers listed (93.855 and 93.856) place the opportunity within allergy/immunology and infectious diseases research domains, reflecting the intersection of atopic dermatitis inflammation with infection susceptibility and immune defense.
What makes this opportunity different from a typical single-project clinical study grant?
This FOA is designed to support an integrated, multi-project, multi-institution network. The emphasis is on coordinated operations, shared standards, and a unified research program structure, rather than independent projects operating separately.
Browse more opportunities from the same category: Health
Next opportunity: Translational Research to Help Older Adults Maintain their Health and Independence in the Community (R21)
Previous opportunity: Cooperative Ecosystem Studies Unit, Gulf Coast CESU
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 033
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 033) also looked into and applied for these:
| Funding Opportunity |
|---|
| Translational Research to Help Older Adults Maintain their Health and Independence in the Community (R21) Apply for PA 14 159 Funding Number: PA 14 159 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Translational Research to Help Older Adults Maintain their Health and Independence in the Community (R01) Apply for PA 14 161 Funding Number: PA 14 161 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Girls Education Strengthen Family and Community Support to Orphans and Vulnerable Children Program Apply for RFA 656 14 000001 Funding Number: RFA 656 14 000001 Agency: Mozambique USAID Maputo Category: Health Funding Amount: $15,864,752 |
| Population based HIV Impact Assessments in Resource Constrained Settings under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1409 Funding Number: CDC RFA GH14 1409 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $25,000,000 |
| Rural Access to Emergency Devices Grant Program Apply for HRSA 14 129 Funding Number: HRSA 14 129 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Public Access to Defibrillation Demonstration Project Apply for HRSA 14 130 Funding Number: HRSA 14 130 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Mali High Impact Health Services II Apply for RFA 688 14 000005 Funding Number: RFA 688 14 000005 Agency: Mali USAID Bamako Category: Health Funding Amount: $45,000,000 |
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2) Apply for RFA AR 14 015 Funding Number: RFA AR 14 015 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3) Apply for RFA AR 14 016 Funding Number: RFA AR 14 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Modeling Immunity for Biodefense (U19) Apply for RFA AI 14 028 Funding Number: RFA AI 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| CDCs National Undergraduate Student Program A Public Helath Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110104CONT14 Funding Number: CDC RFA MN11 110104CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas Apply for CDC RFA CK13 130102CONT14 Funding Number: CDC RFA CK13 130102CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Leveraging a Recovery Act Resource to Accelerate Research on Neurodevelopment (R01) Apply for RFA MH 15 400 Funding Number: RFA MH 15 400 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Provider Education and Public Awareness about Primary Immunodeficiency Disease Apply for CDC RFA OE12 120303CONT14 Funding Number: CDC RFA OE12 120303CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Targeting Latently Infected Cells Without Reactivation (R01) Apply for RFA AI 14 021 Funding Number: RFA AI 14 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Center for HIV, Viral Hepatitis, STD and TB Prevention (NCHHSTP) Apply for CDC RFA PS13 131502CONT14 Funding Number: CDC RFA PS13 131502CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIAID Division of Allergy, Immunology and Transplantation Statistical and Clinical Coordinating Center (UM2) Apply for RFA AI 14 016 Funding Number: RFA AI 14 016 Agency: National Institutes of Health Category: Health Funding Amount: $16,500,000 |
| National Environmental Medicine Education and Consultation Project (NEMECP) Apply for CDC RFA TS14 1401 Funding Number: CDC RFA TS14 1401 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Reduce Hepatitis Infections by Treatment and Integrated Prevention Services (Hepatitis TIPS) among Non urban Young Persons Who Inject Drugs Apply for RFA PS 14 004 Funding Number: RFA PS 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| National Diabetes Prevention Program Preventing Type 2 Diabetes Among People at High Risk Apply for CDC RFA DP12 121203CONT14 Funding Number: CDC RFA DP12 121203CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 033", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.